Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine to Improve Gastric Intestinal Metaplasia and Inhibit Gastric Cancer
jRCTs031250217Active, not recruiting
- Sponsor
- Yokohama City University
- Start
- Oct 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in Intestinal metaplasia and gastric cancer (GC) comparing Berberine + Gennoshouko extract with Drug-free observation (2 arms). Primary endpoint: Improvement rate of histological intestinal metaplasia. Started Oct 2025; status: active, not recruiting.
02
Drugs
berberinegennoshouko extract
03
Conditions
Intestinal metaplasiagastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031250217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250217.